One thing I've figured out today that the crazy doctor is actually right about is that version 2 dates back to 2008 and was part of that data from poster 3 (7-year study). The key piece of info that he won't tell you, however, is that version 2 has not been evaluated under optimal conditions until this current bridging study and even the non-optimal evaluations have promising data as referenced today by GC today when he pointed out that the AD vs cognitive-intact accuracy was actually 90 in the 7-year study. The bridging study will compare AD vs cognitive-intact under better testing conditions and won't involve cohorts that include other dementias like the 7-year study that used Provista's data obtained from a poorly run study. This should provide the data to show that version 2 is a winner. At least that's their theory.
Ive spent way too much time on this last night and today, but I think I understand it pretty well now and believe we will see good data on the 31st.
Please correct me if I am mistaken about the above. Good luck to longs.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links